Hepatitis C Trial Design To Be Discussed By FDA’s Antiviral Drugs Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oct. 19-20 meeting will focus on control arms, endpoints and long-term follow-up.